Picture of Genelux logo

GNLX — Genelux News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Genelux Corp expected to post a loss of 22 cents a share - Earnings Preview

Genelux Corp GNLX.OQ GNLX.O is expected to  show no change in quarterly revenue when it reports  results  for the period ending September 30 2025

​LSEG's mean analyst estimate for Genelux Corp is for a loss of 22 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 3.2% in the last three months. ​

Wall Street's median 12-month price target for Genelux Corp is $13.00, about 74.3% above its last closing price of $3.34

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATEACTUALBEAT, MET, MISSEDSURPRISE %
Jun. 30 2025-0.22-0.21-0.20Beat7
Mar. 31 2025-0.26-0.24-0.21Beat13.4
Dec. 31 2024-0.14-0.18-0.26Missed-42.5​
Sep. 30 2024-0.20-0.19-0.19Met-1.8
​​Jun. 30 2024-0.18-0.19-0.22Missed-15.8
Mar. 31 2024-0.26-0.23-0.29Missed-23.4​
Dec. 31 2023-0.19-0.25Missed-31.6
Sep. 30 2023-0.17-0.18-0.20Missed-13.2
This summary was machine generated August 8 at 20:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Genelux

See all news